AC Immune SANASDAQ:ACIU
- LAST PRICE3.3800
- TODAY'S CHANGE (%)0.0900 (2.7356%)
- Bid / Lots3.1000/ 2
- Ask / Lots3.8400/ 3
- Open / Previous Close3.3000 / 3.2900
- Day Range
- 52 Week Range
- Volume63,256
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACIU |
|---|---|---|
| 09:32 ET | 2560 | 3.3 |
| 09:35 ET | 700 | 3.2473 |
| 09:42 ET | 1402 | 3.29 |
| 09:46 ET | 951 | 3.267 |
| 10:02 ET | 500 | 3.2956 |
| 10:15 ET | 902 | 3.3 |
| 10:18 ET | 1250 | 3.29 |
| 10:31 ET | 114 | 3.28 |
| 11:02 ET | 2299 | 3.3 |
| 11:05 ET | 100 | 3.32 |
| 11:07 ET | 600 | 3.32 |
| 11:12 ET | 100 | 3.33 |
| 11:14 ET | 100 | 3.335 |
| 11:18 ET | 200 | 3.34 |
| 11:25 ET | 100 | 3.34 |
| 11:39 ET | 1046 | 3.35 |
| 11:41 ET | 1521 | 3.35 |
| 11:43 ET | 400 | 3.3692 |
| 11:52 ET | 500 | 3.3872 |
| 12:03 ET | 150 | 3.38 |
| 12:06 ET | 1000 | 3.3713 |
| 12:08 ET | 1400 | 3.38 |
| 12:14 ET | 200 | 3.38 |
| 12:15 ET | 1000 | 3.3875 |
| 12:17 ET | 377 | 3.3957 |
| 12:19 ET | 100 | 3.3707 |
| 12:21 ET | 100 | 3.4 |
| 12:24 ET | 3000 | 3.385 |
| 12:30 ET | 100 | 3.37 |
| 12:32 ET | 152 | 3.38 |
| 12:51 ET | 100 | 3.365 |
| 12:57 ET | 1152 | 3.36 |
| 01:31 ET | 878 | 3.36 |
| 01:40 ET | 954 | 3.3768 |
| 01:42 ET | 200 | 3.36 |
| 01:44 ET | 1091 | 3.36 |
| 02:02 ET | 1000 | 3.36 |
| 02:18 ET | 100 | 3.36 |
| 02:32 ET | 728 | 3.385 |
| 02:38 ET | 229 | 3.385 |
| 02:50 ET | 10316 | 3.38 |
| 02:52 ET | 100 | 3.37 |
| 03:06 ET | 200 | 3.36 |
| 03:12 ET | 1775 | 3.37 |
| 03:14 ET | 1918 | 3.36 |
| 03:21 ET | 1200 | 3.37 |
| 03:28 ET | 200 | 3.378 |
| 03:30 ET | 331 | 3.3752 |
| 03:35 ET | 200 | 3.37 |
| 03:37 ET | 5000 | 3.37 |
| 03:42 ET | 100 | 3.36 |
| 03:46 ET | 125 | 3.365 |
| 03:53 ET | 400 | 3.37 |
| 03:57 ET | 576 | 3.375 |
| 04:00 ET | 2535 | 3.38 |
Nov 15, 2024
DJ AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co., from 6:49AM ET on Friday Nov 15, 2024 by Dow Jones
6:49AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
AC Immune to Present at the Jefferies 2024 London Healthcare Conference, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 6, 2024
DJ AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co., from 6:47AM ET on Wednesday Nov 06, 2024 by Dow Jones
6:47AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Press Release: AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update, from 7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AC Immune SA | 325.5M | -7.3x | --- |
4D Molecular Therapeutics Inc | 415.2M | -2.8x | --- |
Verve Therapeutics Inc | 389.5M | -2.0x | --- |
ProQR Therapeutics NV | 382.3M | -11.8x | --- |
XOMA Royalty Corp | 354.3M | -9.9x | --- |
C4 Therapeutics Inc | 283.1M | -2.5x | --- |
Company Information
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Contact Information
- Headquarters
- EPFL Innovation Park, Building BLAUSANNE, Switzerland 1015
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Douglas Williams
- Chief Executive Officer, Co-Founder, Director
- Andrea Pfeifer
- Chief Financial Officer, Vice President - Finance
- Christopher Roberts
- Chief Technical Operations Officer
- Piergiorgio Donati
- Chief Human Resource Officer
- Howard Donovan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $325.5M |
|---|---|
Revenue (TTM) | $46.2M |
Shares Outstanding | 98.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.24 |
EPS | $-0.46 |
Book Value | $1.83 |
P/E Ratio | -7.3x |
Price/Sales (TTM) | 7.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
